Analysis Tools|
Allele Symbol Allele Name Allele ID |
Rrn3tm1.1Igt targeted mutation 1.1, Ingrid Grummt MGI:3584035 |
||||||||||||||||||||
| Summary |
4 genotypes
|
|
|
| ♀ | phenotype observed in females |
| ♂ | phenotype observed in males |
| N | normal phenotype |
|
|
| ♀ | phenotype observed in females |
| ♂ | phenotype observed in males |
| N | normal phenotype |
|
• nucleolar integrity is disrupted in dopaminergic neurons of tamoxifen treated mice to a similar level as seen in single conditional Rrn3 mutants
|
|
• induction of nucleolar stress is seen in dopaminergic neurons of tamoxifen treated mice to a similar level as seen in single conditional Rrn3 mutants
|
|
|
| ♀ | phenotype observed in females |
| ♂ | phenotype observed in males |
| N | normal phenotype |
|
• motor dysfunction in mice injected with tamoxifen at 2 months of age
|
|
• nucleolar integrity is disrupted in dopaminergic neurons of tamoxifen treated mice
|
|
• about 40% decrease in COX activity is seen 2 weeks after tamoxifen treatment, indicating mitochondrial damage is an early consequence of nucleolar damage
|
|
• induction of nucleolar stress is seen in dopaminergic neurons of tamoxifen treated mice
|
|
• dopaminergic neurons of tamoxifen-induced mice are more vulnerable to the oxidative damage induced by MPTP than controls showing an approximate 40% loss of neurons compared to 15% in controls
|
|
• dopaminergic neurons show higher levels of oxidative stress markers at 4 weeks after tamoxifen treatment
|
|
• mice injected with tamoxifen at 2 months of age exhibit a decline in dopamine content in the striatum
|
|
• mice injected with tamoxifen at 2 months of age show a progressive differential loss of dopaminergic neurons in substantia nigra and ventral tegmental area
• tamoxifen-induced mice treated with pifithrin-alpha, a chemical inhibitor of Trp53 show prevention of dopaminergic neuron loss
|
|
• mice injected with tamoxifen at 2 months of age exhibit neurodegeneration of TH+ neurons
|
Mouse Models of Human Disease |
DO ID | OMIM ID(s) | Ref(s) | |
| Parkinson's disease | DOID:14330 |
OMIM:PS168600 |
J:168232 , J:242309 | |
|
|
| ♀ | phenotype observed in females |
| ♂ | phenotype observed in males |
| N | normal phenotype |
|
• mice exhibit abnormal behavior at 4 weeks of age, starting with slowness of movements
|
|
• mice show an approximate 55% reduction in motor performance on the accelerating rotarod at 4 weeks of age, reaching a 76% decline at 8 weeks of age
|
|
• mice eventually develop twitching similar to Parkinsons disease tremor
|
|
• mice exhibit posture disturbances at 4 weeks of age
|
|
• mice exhibit abnormal gait at 4 weeks of age
|
|
• nucleolar disruption in dopaminergic neurons is seen at E18.5
|
|
• mice show a progressive reduction in weight gain after P15
• mice with severe phenotype treated with the dopamine precursor L-DOPA survive and grain weight
|
|
• 95% reduction of dopamine levels at 5 weeks of age
|
|
• decrease in the number of dopaminergic neurons, with neurons in the substantia nigra more rapidly and severely affected than those in the ventral tegmental area
• TH immunoreactivity in dopaminergic neuron terminals in the striatum is decreased already at P0, before the loss of neurons
|
|
• of dopaminergic neurons
|
Mouse Models of Human Disease |
DO ID | OMIM ID(s) | Ref(s) | |
| Parkinson's disease | DOID:14330 |
OMIM:PS168600 |
J:168232 | |
Mouse Genome Database (MGD), Gene Expression Database (GXD), Mouse Models of Human Cancer database (MMHCdb) (formerly Mouse Tumor Biology (MTB)), Gene Ontology (GO) |
||
|
Citing These Resources Funding Information Warranty Disclaimer, Privacy Notice, Licensing, & Copyright Send questions and comments to User Support. |
last database update 12/10/2024 MGI 6.24 |
|
|
|
||
